ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Combined therapy with nebulized and intravenous colistin for the treatment of multidrug resistance pneumonia in burn patients: experience from a third referral burn care center in Mexico City.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeNebulized colistin has shown promise in treating ventilator-associated pneumonia (VAP) due to carbapenem-resistant strains; evidence in burn patients is limited. This study evaluated the efficacy of nebulized colistin as an adjunct to intravenous colistin in burn patients with pneumonia caused by multidrug-resistant (MDR) Gram-negative bacteria. MATERIALS AND
methodsA retrospective cohort was conducted at a burn center in Mexico City (August 2011-May 2017). Patients diagnosed with VAP or hospital-acquired pneumonia (HAP) due to MDR rods, treated during this period with nebulized colistin plus intravenous colistin or intravenous colistin alone, were included. Clinical response and complications were evaluated on days 2, 5, and 10. Thirty-day survival was analyzed using the Kaplan-Meier method.
resultsFifty patients were included; 41 developed VAP and 9 HAP; combined therapy group included 31 patients. Thermal burns predominated, with airway injury in 26%. Among 65 isolates, Acinetobacter baumannii (n = 28) and Pseudomonas aeruginosa (n = 27) were frequent. Combined therapy was associated with higher frequency of acute respiratory distress syndrome events (61% vs. 32%, p = 0.041), vasopressor use (27% vs. 11%, p = 0.010), longer mechanical ventilation (median 27 vs. 10 days, p = 0.005), elevated SOFA scores (median 3 vs. 1, p < 0.001), and prolonged ICU stay (median 42 vs. 26 days, p = 0.025). Bronchospasm occurred in 13% and alveolar hemorrhage in one patient. No difference in 30-day mortality was observed (log-rank p = 0.63).
conclusionAdding nebulized colistin to intravenous therapy did not improve outcomes in burn patients with multidrug-resistant Gram-negative pneumonia. Prospective studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.